Blood cancers, a category that includes polycythemia vera (PV), are a risk factor for severe COVID-19. As such, managing your risk and taking steps to prevent COVID-19 if you have PV are important ...

Patients with blood cancers like polycythemia vera, a kind of myeloproliferative neoplasm, may benefit in learning more about ...

During a live event, Mojtaba Akhtari, MD, discussed trials studying patients with high-risk polycythemia vera.

Polycythemia vera treatments help reduce your risk of symptoms and complications. But for some people, the disease still gets worse and turns into another blood cancer, despite treatment.

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. Several medications are approved to treat ...

Many people with polycythemia vera (PV) live a normal life with this rare blood cancer under control. The goal is to avoid complications like blood clots, which may happen because PV thickens your ...

Just like any chronic health condition, polycythemia vera (PV) can have a negative impact on your everyday life. Research has shown that PV is associated with a lower quality of life in measures ...

Non-JAK2 mutations, particularly in SRSF2, ASXL1, and IDH2, were independently associated with worse survival outcomes in ...

THE course of polycythemia vera is complicated by hemorrhagic and thromboembolic phenomena of varying severity occurring in about a third of the cases. These complications have been ascribed to the ...

However, polycythemia vera is a myeloproliferative disorder, a type of blood cancer caused by a mutation in the JAK2 gene. This causes excess development of red blood cells. People with P. vera are at ...

WINTROBE1 has reported that cases of polycythemia vera have been described early in life, but evidence that they are not examples of secondary polycythemia has seldom been presented. He states that ...

However, polycythemia vera is a myeloproliferative disorder, a type of blood cancer caused by a mutation in the JAK2 gene. This causes excess development of red blood cells.